Special Issue

Glutamate Receptor in Health and Development

Message from the Guest Editor

Glutamate is an essential excitatory neurotransmitter in the central nervous system that is involved indispensably in neuronal development and memory formation. Glutamate receptors, which mediate major excitatory synaptic transmission, regulate a wide spectrum of biological processes in normal development and health. The dysregulation of glutamate receptors and the glutamatergic system is involved in numerous neurological and psychiatric disorders. There are two main classes of glutamate receptors, ionotropic and metabotropic (mGluRs) receptors. The former stimulate fast excitatory neurotransmission and include N-methyl-D-aspartate (NMDA), □-amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA) and kainite; while the latter are G protein-coupled receptors mediating glutamatergic activity via intracellular messenger systems. In this Special Issue, we wish to focus on a broad spectrum of basic and clinical studies on glutamate receptors in human development, health and disease.

Guest Editor

Dr. Chin-Wei Huang

Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan

Deadline for manuscript submissions

closed (31 July 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/si/110914

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).